Thursday, June 2, 2011
Profectus BioSciences Inc., of Baltimore, and the HIV Vaccine Trials Network started a Phase I HIV vaccine study involving a recombinant vesicular stomatitis virus that expresses the HIV-1 gag protein. Sixty HIV-uninfected adults will be enrolled, and the trial will evaluate safety and immunogenicity of increasing doses of the vaccine. The study is being sponsored by the National Institute of Allergy and Infectious Diseases.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.